Subsequent Malignant Neoplasms After Hematopoietic Cell Transplantation

and, Smita Bhatia; Bhatia, Ravi

doi:10.1002/9781118416426.ch104

Cited by 4 publications

(11 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of PTLD after allo‐HSCT is also associated with the presence of EBV . We have found EBV in the lymph nodes in our patients who had PTLD.…”

Section: Discussionsupporting

confidence: 49%

“…Post‐transplant lymphoproliferative disease incidence is between 1% and 2% at 10 years after allo‐HSCT . We calculated the incidences for all subsequent malignancy as 3.9% at 10 years after allo‐HSCT and for PTLD as 0.5% at 10 years.…”

Section: Discussionmentioning

confidence: 99%

“…For decades, allogeneic hematopoietic stem cell transplantation (allo‐HSCT) has been performed in many patients with various benign or malignant hematological diseases and has increased patient survival . However, due to the increased survival, late complications, including subsequent malignancy, have appeared as an important issue in allo‐HSCT patients . Although very rare, mortality associated with subsequent malignancy is an important problem …”

Section: Introductionmentioning

confidence: 99%

“…However, due to the increased survival, late complications, including subsequent malignancy, have appeared as an important issue in allo‐HSCT patients . Although very rare, mortality associated with subsequent malignancy is an important problem …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Subsequent malignancies after allogeneic hematopoietic stem cell transplantation

Gündüz¹,

Ozen

Şahin

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

We evaluated 979 patients for the development of post-transplant lymphoproliferative disease (PTLD) and solid malignancies after allogeneic hematopoietic stem cell transplantations (allo-HSCT) as a late complication. We found 15 (1.5%) subsequent malignancies; three of these malignancies were PTLD, and twelve were solid tumors. The median time from allo-HSCT to the development of PTLD was 9 (3-20) months and that from allo-HSCT to the development of solid tumors was 93 (6-316) months. The cumulative incidence of evolving subsequent malignancy in patients was 1.3% (±0.5 SE) at 5 years and 3.9% (±1.2 SE) at 10 years. The cumulative incidence of developing subsequent malignancy in patients with benign hematological diseases as the transplant indication was 7.4%±4.2 SE at 5 years. More subsequent malignancy developed in patients having ≥1 year chronic graft-vs-host disease (GVHD; 3.7% in ≥1 year chronic GVHD and 0.7% in <1 year chronic GVHD patient groups, P=.002). Subsequent epithelial tumor risk was higher in ≥1 year chronic GVHD patients than <1 year (3.7% vs 0.1%, P<.001). In multivariate analysis, benign hematological diseases as transplant indication (RR: 5.6, CI 95%: 1.4-22.3, P=.015) and ≥1 year chronic GVHD (RR: 7.1, 95% CI: 2.3-22.5, P=.001) were associated with the development of subsequent malignancy.

show abstract

“…The development of PTLD after allo‐HSCT is also associated with the presence of EBV . We have found EBV in the lymph nodes in our patients who had PTLD.…”

Section: Discussionsupporting

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Subsequent malignancies after allogeneic hematopoietic stem cell transplantation

Gündüz¹,

Ozen

Şahin

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…HSCT recipients are at increased risk of developing therapy-related myelodysplastic syndrome, acute myeloid leukemia, PTLDs, and solid cancers. 98 The cumulative incidence of PTLDs reaches 1% 6 0.3% at 10 years after allogeneic bone marrow transplant, with the highest incidence occurring 1 to 5 months post transplant. 99 Overall, the risk of developing new solid cancers after allogeneic bone marrow transplant is 2-fold as compared with the general population.…”

Section: Secondary Malignanciesmentioning

confidence: 99%

Pathology of Gastrointestinal and Liver Complications of Hematopoietic Stem Cell Transplantation

Mourad

Michel

Marcus

2019

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Despite advances in therapeutic and preventive measures, hematopoietic stem cell transplant recipients remain at risk for a variety of gastrointestinal and liver complications. Objective.— To detail the pathologic features of the various gastrointestinal and liver complications occurring after hematopoietic stem cell transplantation in relation to their clinical context. The specific complications covered include graft-versus-host disease, mycophenolate mofetil–induced injury, timeline of infections, neutropenic enterocolitis, gastrointestinal thrombotic microangiopathy, sinusoidal obstruction syndrome, hepatic iron overload, and the controversy around cord colitis syndrome. Data Sources.— The content of this article is based on pertinent peer-reviewed articles in PubMed, relevant textbooks, and on the authors' personal experiences. Conclusions.— The final histopathologic diagnosis requires the integration of clinical and histologic findings and the exclusion of other competing causes of injury. Review of the clinical data, including the original disease pretransplant, the type of transplant, the timing of the gastrointestinal and/or liver manifestations, the timing of the biopsy after transplant, the presence of graft-versus-host disease in other organs and sites, the list of drug regimens, and the clinical and laboratory evidence of infection, is the key to reaching the proper histologic diagnosis.

show abstract

Hematopoietic Cell Transplantation

Petersdorf

2023

Palliative Care in Hematologic Malignancies and Serious Blood Disorders

View full text Add to dashboard Cite

Subsequent Malignant Neoplasms After Hematopoietic Cell Transplantation

Cited by 4 publications

References 150 publications

Subsequent malignancies after allogeneic hematopoietic stem cell transplantation

Subsequent malignancies after allogeneic hematopoietic stem cell transplantation

Pathology of Gastrointestinal and Liver Complications of Hematopoietic Stem Cell Transplantation

Hematopoietic Cell Transplantation

Contact Info

Product

Resources

About